Visual abstract | Phase III PHOENYCS GO trial: Dapirolizumab pegol in SLE

Dapirolizumab pegol is a polyethylene glycol (PEG)-conjugated antigen-binding fragment (Fab) that binds to CD40 ligand (CD40L), thereby blocking CD40–CD40L signaling, an important pathway involved in immune-cell activation and implicated in systemic lupus erythematosus (SLE) pathogenesis.¹  

The global, randomized, double-blind, placebo-controlled, phase III PHOENYCS GO trial (NCT04294667) evaluated the efficacy and safety of dapirolizumab pegol + standard of care (SoC) vs placebo + SoC in patients with moderate-to-severe, active SLE.¹ The trial met its primary endpoint, with dapirolizumab pegol + SoC demonstrating a significantly greater British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response at Week 48 vs placebo + SoC (50% vs 35%; p = 0.011). Here we present a visual abstract summarizing the key efficacy and safety results from the PHOENYCS GO trial published in The Lancet by Clowse et al. 

This educational resource is independently supported by Biogen and UCB. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.